Acadia said remlifanserin missed a mid-stage trial’s main goal for Alzheimer’s psychosis: 60 mg improved hallucinations and delusions versus placebo, but not enough after six weeks. The result was statistically significant on a key secondary measure of psychosis severity.
The 30-mg once-daily dose showed little improvement versus placebo, and Acadia will stop testing it. The company said it will continue enrolling patients in two ongoing late-stage studies of remlifanserin for Alzheimer’s psychosis.
Acadia said side-effect rates, serious side effects and treatment discontinuations were similar to placebo. It reported no apparent effects on patients’ movement or cognitive function and no deaths among those receiving the drug. Acadia shares fell about 12% in premarket trading.
